# Khartis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/khartis-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.khartis.com
- Total disclosed funding: $50M
- Latest round: Series B (Aug 13, 2026)
- Investors on record: 6

## About

Based in the US, Founded in 2024 by Robert Hoffman (CEO and Head of Drug Discovery) Craig Murphy (CSO), and Chris LeMasters (Executive Chairman) in San Diego, California, US. Khartis Therapeutics, Inc. operates as a biotechnology company that provides oral drug therapies for immune-mediated and chronic diseases.
The company will use the August 2026 funding to advance its lead oral, selective IGF-1R inhibitor for thyroid eye disease and continue developing its broader pipeline of oral small-molecule medicines targeting clinically validated immunology pathways.

## Funding rounds

- Series B, Aug 13, 2026, $50M — Alexandria Venture Investments, Lilly Asia Ventures, Nextech, Longwood Fund, Foresite Capital, Forge Life Science Partners

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Forge Life Science Partners (https://capitalatlas.ai/funds/forge-life-science-partners) — Series B